Discover and read the best of Twitter Threads about #TME
Most recents (2)
#OncoAlert Exploration of the impact of #EGFR TKIs on the #TME @CCR_AACR. Analysis of 138 patients with EGFR+ #NSCLC who received a 1st gen EGFR TKI and had pre/post biopsies. Assayed changes in PD-L1 expression, TIL density and TME makeup. #LCSM
clincancerres.aacrjournals.org/content/early/…
clincancerres.aacrjournals.org/content/early/…
@CCR_AACR In general, samples taken post 1st gen TKI had higher PDL1 expression but induction of strong PDL1 expression accompanied by increase in Treg density and CD73 expression. Understanding the TME will allow us to unlock IO benefit (and explain the toxicity when IO precedes TKI). 
@CCR_AACR PDL1 upregulation more common in context of T790M negative resistance. Interestingly, potentially different impact when osimertinib given (no CD73 upregulation). Does our choice of EGFR TKI impact potential efficacy of IO therapy in the future? So many variables to consider!
Intriguing article in the June issue of @JTOonline by #JongWooLee and @DrRoyHerbstYale tackling the impact of #KRAS on the immune microenvironment in #NSCLC and the rationale for combining #MEK inhibition and anti-PD(L)1 therapy. #OncoAlert #LCSM
jto.org/article/S1556-…
jto.org/article/S1556-…
Authors induced a p53/KRAS G12D mutant NSCLC. Compared to tumor free lungs, see a stark increase in CD45+ cells. Note, geographically localized to periphery/margin. Translational challenge: easy to miss with biopsies(aspirates not helpful).
Specifically, there’s a rise in neutrophils and MDSCs and a decrease in CD3+/CD8+ T cells in the tumor bearing lung (red bars below). Accompanied by rise in PDL1 expression (in tumor and MDSCs). Story: does this immune cell accumulation precede tumor development? Is it required?
